Search
| Leader | 00000nz a2200037n 45 0 | ||
|---|---|---|---|
| 001 | WKP|Q89035894 (VIAF cluster) (Authority/Source Record) | ||
| 003 | WKP | ||
| 005 | 20241121000152.0 | ||
| 008 | 241121nneanz||abbn n and d | ||
| 035 | ‡a (WKP)Q89035894 | ||
| 024 | ‡a 0000-0003-0667-1596 ‡2 orcid | ||
| 035 | ‡a (OCoLC)Q89035894 | ||
| 100 | 0 | ‡a অ্যান্ড্রু জে স্টিল ‡9 bn | |
| 375 | ‡a 1 ‡2 iso5218 | ||
| 400 | 0 | ‡a Andrew J Steele ‡c researcher (ORCID 0000-0003-0667-1596) ‡9 en | |
| 400 | 0 | ‡a Andrew J Steele ‡c wetenschapper ‡9 nl | |
| 670 | ‡a Author's Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis | ||
| 670 | ‡a Author's BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia | ||
| 670 | ‡a Author's Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials | ||
| 670 | ‡a Author's Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial | ||
| 670 | ‡a Author's Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors | ||
| 670 | ‡a Author's Ibrutinib therapy releases leukemic surface IgM from antigen drive in chronic lymphocytic leukemia patients | ||
| 670 | ‡a Author's IL-4 enhances expression and function of surface IgM in CLL cells. | ||
| 670 | ‡a Author's PI3K in CLL: are 2 isoforms better than 1? | ||
| 670 | ‡a Author's Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells | ||
| 670 | ‡a Author's Releasing the brakes on BTK-targeting miRNA. | ||
| 670 | ‡a Author's Roring ahead with DOCK2 | ||
| 670 | ‡a Author's The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model | ||
| 670 | ‡a Author's To BH3 profile or not to BH3 profile | ||
| 909 | ‡a (orcid) 0000000306671596 ‡9 1 | ||
| 919 | ‡a tobh3profileornottobh3profile ‡A To BH3 profile or not to BH3 profile ‡9 1 | ||
| 919 | ‡a releasingthebrakesonbtktargetingmirna ‡A Releasing the brakes on BTK-targeting miRNA. ‡9 1 | ||
| 919 | ‡a preclinicalevaluationofanovelship1phosphataseactivatorforinhibitionofpi3ksignalinginmalignantbcells ‡A Preclinical Evaluation of a Novel SHIP1 Phosphatase Activator for Inhibition of PI3K Signaling in Malignant B Cells ‡9 1 | ||
| 919 | ‡a 4enhancesexpressionandfunctionofsurfaceigmincllcells ‡A IL-4 enhances expression and function of surface IgM in CLL cells. ‡9 1 | ||
| 919 | ‡a ibrutinibtherapyreleasesleukemicsurfaceigmfromantigendriveinchroniclymphocyticleukemiapatients ‡A Ibrutinib therapy releases leukemic surface IgM from antigen drive in chronic lymphocytic leukemia patients ‡9 1 | ||
| 919 | ‡a developmentofprotacstoaddressclinicallimitationsassociatedwithbtktargetedkinaseinhibitors ‡A Development of PROTACs to address clinical limitations associated with BTK-targeted kinase inhibitors ‡9 1 | ||
| 919 | ‡a clinicalsignificanceoftp53birc3atmandmapkerkgenesinchroniclymphocyticleukaemiadatafromtherandomiseduklrfcll4trial ‡A Clinical significance of TP53, BIRC3, ATM and MAPK-ERK genes in chronic lymphocytic leukaemia: data from the randomised UK LRF CLL4 trial ‡9 1 | ||
| 919 | ‡a clinicalsignificanceofdnamethylationinchroniclymphocyticleukemiapatientsresultsfrom3ukclinicaltrials ‡A Clinical significance of DNA methylation in chronic lymphocytic leukemia patients: results from 3 UK clinical trials ‡9 1 | ||
| 919 | ‡a bcrsignalingcontributestoautophagyregulationinchroniclymphocyticleukemia ‡A BCR signaling contributes to autophagy regulation in chronic lymphocytic leukemia ‡9 1 | ||
| 919 | ‡a autophagyinhibitionmediatedepithelialmesenchymaltransitionaugmentslocalmyofibroblastdifferentiationinpulmonaryfibrosis ‡A Autophagy inhibition-mediated epithelial-mesenchymal transition augments local myofibroblast differentiation in pulmonary fibrosis ‡9 1 | ||
| 919 | ‡a pi3kincllare2isoformsbetterthan1 ‡A PI3K in CLL: are 2 isoforms better than 1? ‡9 1 | ||
| 919 | ‡a roringaheadwithdock2 ‡A Roring ahead with DOCK2 ‡9 1 | ||
| 919 | ‡a pi3kmtorinhibitorpf04691502inducesapoptosisandinhibitsmicroenvironmentalsignalingincllandtheeμtcl1mousemodel ‡A The PI3K/mTOR inhibitor PF-04691502 induces apoptosis and inhibits microenvironmental signaling in CLL and the Eµ-TCL1 mouse model ‡9 1 | ||
| 946 | ‡a b ‡9 1 | ||
| 996 | ‡2 ISNI|0000000038704581 | ||
| 996 | ‡2 LC|no2012109090 | ||
| 996 | ‡2 DNB|1231919701 | ||
| 996 | ‡2 LC|n 92057298 | ||
| 996 | ‡2 NDL|00475543 | ||
| 996 | ‡2 N6I|vtls002270527 | ||
| 996 | ‡2 SUDOC|231735057 | ||
| 996 | ‡2 LIH|LNB:BOV_v_;=B_z_ | ||
| 996 | ‡2 ISNI|0000000034630415 | ||
| 996 | ‡2 LC|nb2008014621 | ||
| 996 | ‡2 ISNI|0000000031909920 | ||
| 996 | ‡2 ISNI|0000000042301347 | ||
| 996 | ‡2 PLWABN|9810624558305606 | ||
| 996 | ‡2 ISNI|0000000030643163 | ||
| 996 | ‡2 BIBSYS|14059155 | ||
| 996 | ‡2 ISNI|0000000038383618 | ||
| 996 | ‡2 LC|nb2021011868 | ||
| 996 | ‡2 BIBSYS|90316608 | ||
| 996 | ‡2 LIH|LNB:DL_i_5;=BU | ||
| 996 | ‡2 NTA|436280981 | ||
| 996 | ‡2 LC|nb2012016024 | ||
| 996 | ‡2 NUKAT|n 2016007326 | ||
| 996 | ‡2 LC|no2009097184 | ||
| 996 | ‡2 DNB|1038828457 | ||
| 996 | ‡2 ISNI|0000000447482406 | ||
| 996 | ‡2 PTBNP|1767016 | ||
| 996 | ‡2 LC|no2002003664 | ||
| 996 | ‡2 J9U|987007352032905171 | ||
| 996 | ‡2 NKC|xx0275620 | ||
| 996 | ‡2 BIBSYS|90119625 | ||
| 996 | ‡2 LC|nr 92002329 | ||
| 996 | ‡2 LC|n 82054624 | ||
| 996 | ‡2 NSK|000536117 | ||
| 996 | ‡2 LC|nb2011017062 | ||
| 996 | ‡2 SUDOC|186011148 | ||
| 996 | ‡2 LC|nb2021013533 | ||
| 996 | ‡2 CAOONL|ncf10087509 | ||
| 996 | ‡2 LC|n 2003017100 | ||
| 996 | ‡2 NDL|032543397 | ||
| 996 | ‡2 BNF|12186242 | ||
| 996 | ‡2 ISNI|0000000409324255 | ||
| 996 | ‡2 LC|n 2015183041 | ||
| 996 | ‡2 LC|n 86074697 | ||
| 996 | ‡2 ISNI|0000000039272186 | ||
| 996 | ‡2 SUDOC|074169262 | ||
| 996 | ‡2 NII|DA00992575 | ||
| 996 | ‡2 RERO|A012380628 | ||
| 996 | ‡2 BNC|981060407700206706 | ||
| 996 | ‡2 PTBNP|1843447 | ||
| 996 | ‡2 N6I|vtls001361823 | ||
| 996 | ‡2 LC|no2017121233 | ||
| 996 | ‡2 BAV|495_278960 | ||
| 996 | ‡2 LC|nb2016014269 | ||
| 996 | ‡2 ISNI|0000000381255031 | ||
| 996 | ‡2 RERO|A017491066 | ||
| 996 | ‡2 BIBSYS|1632996805653 | ||
| 996 | ‡2 J9U|987012095560805171 | ||
| 996 | ‡2 BIBSYS|90084986 | ||
| 996 | ‡2 RERO|A005566630 | ||
| 996 | ‡2 LC|no2021041292 | ||
| 996 | ‡2 LC|no2013135903 | ||
| 996 | ‡2 CAOONL|ncf10484119 | ||
| 996 | ‡2 N6I|vtls000118012 | ||
| 996 | ‡2 DBC|87097969708196 | ||
| 996 | ‡2 BIBSYS|90808936 | ||
| 996 | ‡2 LC|no2021114973 | ||
| 997 | ‡a 0 0 lived 0 0 ‡9 1 |
